{"title": "BRIEF-Corline Biomedical: Results Of First Study Of Drug Candidate Renaparin", "author": "Reuters Staff", "url": "https://www.reuters.com/article/brief-corline-biomedical-results-of-firs-idUKFWN2DN0DM", "hostname": "reuters.com", "description": "* DRUG CANDIDATE RENAPARIN SHOWS GOOD SAFETY PROFILE IN FIRST STUDY ON PATIENTS", "sitename": "Reuters", "date": "2020-06-10", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "June 10 (Reuters) - Corline Biomedical AB:\n* DRUG CANDIDATE RENAPARIN SHOWS GOOD SAFETY PROFILE IN FIRST STUDY ON PATIENTS\n* RENAPARIN HAS GOOD RESULTS FOR BOTH PRIMARY AND SECONDARY PHASE 1 ENDPOINTS\n* NEXT STEP IN DEVELOPMENT OF RENAPARIN EXPECTED TO BE COMMUNICATED IN SEPTEMBER 2020 Source text for Eikon: Further company coverage: (Gdansk Newsroom)\nOur Standards:\n[The Thomson Reuters Trust Principles.](http://thomsonreuters.com/en/about-us/trust-principles.html)", "language": null, "image": "https://s1.reutersmedia.net/resources_v2/images/rcom-default.png?w=800", "pagetype": "article", "links": ["https://www.thomsonreuters.com/en/global-gateway.html", "https://www.thomsonreuters.com/en/login.html", "https://reuters.zendesk.com/hc/en-us/articles/216467423-Contact-Reuters", "https://reuters.zendesk.com/hc/en-us", "https://www.reuters.com/news/archive/healthcareSector", "http://thomsonreuters.com/en/about-us/trust-principles.html", "//www.reuters.com/tools/mobile", "//newslink.reuters.com/join/subscribe", "//sales.reuters.com/en/ ", "//www.reuters.com/advertising-guidelines", "https://www.thomsonreuters.com/en/privacy-statement.html#cookies", "//www.reuters.com/terms-of-use", "https://www.thomsonreuters.com/en/privacy-statement.html", "javascript:window.OneTrust.ToggleInfoDisplay();", "https://www.reuters.com/info/disclaimer", "https://thomsonreuters.com/copyright/"]}